Abstract
For the purpose of predicting clinical outcomes in patients with diabetes and chronic kidney disease, change in albuminuria is a good candidate to be a surrogate marker for future cardiovascular events and progression of kidney disease. Spot urine albumin/creatinine ratio is convenient and recognized as a viable alternative to 24-h albumin, with some limitations. Although there is sufficient evidence to validate its use in clinical trials as a surrogate endpoint for renal outcomes, this is not yet the case for cardiovascular outcomes. While change in albuminuria as a primary or secondary endpoint is trial-specific, its use should be encouraged, nonetheless.
Original language | English (US) |
---|---|
Pages (from-to) | 1434-1443 |
Number of pages | 10 |
Journal | Diabetes, Obesity and Metabolism |
Volume | 25 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2023 |
Keywords
- albuminuria
- cardiovascular disease
- chronic kidney disease
- diabetes complications
- diabetic nephropathy
- effectiveness
- type 2 diabetes mellitus
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology